Back to discover
Disease
Enterocolitis
Late-stage therapeutic developmentEmerging research
1
Publications
18
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
Research2023-11-01The New England journal of medicine
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Single-Arm, Open-Label, Phase 1 Study to Assess Safety and Preliminary Efficacy of Cultivated Multi-Strain Live Bacterial Therapeutic SER-155 for First-Line Treatment of Immunotherapy-Related Enterocolitis
- Q2 2029Randomized, Controlled, Phase 1-2 Open Label Study of ST266 IV Administration to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Major developments
Major trial resultsHigh impact
Results posted2026-03-12
Major clinical milestoneHigh impact
Efficacy of Early Administration of Hydrocortisone in Shock in Preterm Neonates of Less Than 1,500 g
Primary completion2026-06-30
Clinical MilestonesViewHide
Results posted
- 2026-03-12Effect of Antibiotics on Submucosal Enteric Neurons and Glia in the Lower GastrointestinalResults posted
Results expected
- 2026-04-13Randomized, Controlled, Phase 1-2 Open Label Study of ST266 IV Administration to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)Results expected Q2 2029
- 2025-12-02A Single-Arm, Open-Label, Phase 1 Study to Assess Safety and Preliminary Efficacy of Cultivated Multi-Strain Live Bacterial Therapeutic SER-155 for First-Line Treatment of Immunotherapy-Related EnterocolitisResults expected Q1 2027
Recently completed
- 2026-06-30Efficacy of Early Administration of Hydrocortisone in Shock in Preterm Neonates of Less Than 1,500 gPrimary completion
- 2025-10-15Evaluation of the Clinical and Growth-related Effects of Probiotics in Preterm Infants: A Randomized, Placebo Controlled Clinical Trial.Completed
- 2025-10-14A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsPrimary completion
Activity timeline7
- 2029-03-01ClinicalA Randomized, Controlled, Double-Blind Phase I Clinical Study of Chondroitin Sulfate Supplementation for Treatment of Necrotizing EnterocolitisWithdrawn
- 2026-06-30ClinicalEfficacy of Early Administration of Hydrocortisone in Shock in Preterm Neonates of Less Than 1,500 gPrimary completion
- 2026-04-13ClinicalRandomized, Controlled, Phase 1-2 Open Label Study of ST266 IV Administration to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)Results expected Q2 2029
- 2026-03-12ClinicalEffect of Antibiotics on Submucosal Enteric Neurons and Glia in the Lower GastrointestinalResults posted
- 2025-12-02ClinicalA Single-Arm, Open-Label, Phase 1 Study to Assess Safety and Preliminary Efficacy of Cultivated Multi-Strain Live Bacterial Therapeutic SER-155 for First-Line Treatment of Immunotherapy-Related EnterocolitisResults expected Q1 2027
- 2025-10-15ClinicalEvaluation of the Clinical and Growth-related Effects of Probiotics in Preterm Infants: A Randomized, Placebo Controlled Clinical Trial.Completed
- 2025-10-14ClinicalA Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
5
11
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Recent publications
Major themes3
- Gastroenteritis1
- Immune Checkpoint Inhibitors1
- Neoplasms1
Leading journals1
- The New England journal of medicine1
Leading researchers8
- Amant F1
- Baarslag MA1
- Beijnen JH1
- Borgers JSW1
- Buitelaar PLM1
- de Groot JWB1
- Gierenz N1
- Haanen JBAG1
Affiliations (unnormalised)1
- Amalia Children's Hospital1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.